A laboratory reports a likely pathogenic variant in a gene for a dominant cardiac condition. The classification is careful: the variant is rare, predicted damaging, in a functional domain, and reported once before in a patient with a similar phenotype. The family is counselled and relatives are tested. Two years later an expert panel reviews the gene itself and finds the evidence that it causes the condition at all to be limited: three old case reports, one of them the one the laboratory cited, and no segregation or functional data that survive scrutiny.
The variant classification was defensible. The gene it was built on was not, and nobody had asked.
What the field knows
The variant interpretation framework assumes an established gene. Richards and colleagues (2015) state that the guidelines apply to variants in genes with a known association with the disease in question, and that assessing the association is a separate exercise. The ClinGen gene-disease validity framework (Strande et al., 2017) is that exercise: a structured scoring of genetic evidence, case reports, segregation, de novo observations, and experimental evidence, into categories from no reported evidence through limited, moderate, strong and definitive, with a formal path for a gene to be disputed or refuted.
When genes on existing clinical panels were put through the framework, the results were sobering. Hosseini and colleagues (2018), re-evaluating the genes on long QT syndrome panels, found that a substantial share had limited or disputed evidence, and the same pattern appeared in other cardiac and neurological panels: genes added to panels in the early years on thin evidence had stayed there, and variants in them had been reported to families as pathogenic. The GenCC (DiStefano et al., 2022) brought together gene-disease assertions from multiple curating groups, with their levels and their disagreements, so that a laboratory can see at a glance whether a gene's association is definitive or contested.
The consequence for interpretation is direct. A variant in a gene with limited validity cannot be more than uncertain for that disease, whatever its own properties, because the chain of inference from variant to disease has a weak link that no amount of variant-level evidence repairs. The ClinGen guidance on evidence sources (Biesecker and Harrison, 2018) and the panel re-evaluations both recommend that validity be checked before classification and stated with it.
Validity is also specific to the disease. A gene can be definitive for one condition and limited for another, and a variant found in a patient with the second condition inherits only the second level. The curated resources record the assertion per gene-disease pair for this reason, and a lookup by gene alone can return a reassuring answer to the wrong question. The cardiac gene in the opening case had moderate validity for a different arrhythmia and limited validity for the one the patient had.
Where practice breaks
Validity is assumed from the panel. If a gene is on the laboratory's cardiac panel it is treated as a cardiac gene, and the question of how it got there is not asked. Panels were assembled over years from the literature as it stood, and few have been pruned as the literature was re-evaluated. Removing a gene from a panel is also harder than adding one, because every variant ever reported in it becomes a conversation.
The pipeline annotates the association and not its strength. A gene-disease link is shown as present, from a database that lists associations without curating them, and a link with one case report looks the same as one with hundreds of families. The scientist sees that the gene is associated with the phenotype and reads that as settled.
The variant evidence feels like enough. A rare, predicted-damaging variant in a domain, with a prior report, is a satisfying picture, and the satisfaction is spent on the variant. The prior report may be the only evidence that the gene matters, in which case it is being counted twice: once as evidence for the gene and once as evidence for the variant.
Reclassification of a gene reaches families last. When a gene is downgraded to limited or disputed, every variant reported in it for that disease needs revisiting, and the laboratories that reported them often have no register that links a gene to the families who were told about it. The relatives tested on the strength of the original report are harder still to find, since they are patients of other clinics with results that point back to a proband.
How Tulparus handles it
Gene-disease validity is a field on every candidate, drawn from the curated resources at a named release, with the curating body, the level and the date of the assertion, and with disagreements between curators shown rather than resolved. A candidate in a gene with no assertion, or a limited or disputed one, is flagged at the top of its page before any variant evidence is shown, and the hypothesis built on it carries the validity level as part of its standing.
The classification cannot outrun the gene. Where validity for the condition in question is below moderate, the workbench caps the standing of the hypothesis and says why, and the report, rendered from the case, states the gene-disease validity level beside the variant classification in words a clinician can act on. A likely pathogenic variant in a gene of limited validity would be reported as exactly that, with the consequence for counselling spelled out.
Validity changes trigger review. When a curating body upgrades, downgrades or disputes an association, the knowledge release carries the change, and every case that reported or considered a variant in that gene for that condition appears in the reanalysis queue with the reason. The family in the opening case would have been on that list the week the panel published.
For a gene with no assertion, the candidate is handled under the novel-gene standard rather than as an established one, which is what it is. The distinction is kept on the page and in the report, so that a research lead is never mistaken for an established diagnosis by a reader two years on.
What you can do tomorrow
The resources are public and the check takes a minute per gene.
- Before classifying a variant, look up the gene-disease validity for the specific condition in the curated resources, and write the level and the date into the case note.
- Put the validity level on the report, beside the classification. A clinician should never learn from an expert panel what the laboratory could have said.
- Review your panels against current validity assertions, and decide in writing what to do with limited and disputed genes.
- Keep a register of reported variants by gene and condition, so that a change in validity can be traced to the families it affects.
Sources
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 2015.
- Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource. American Journal of Human Genetics, 2017.
- Hosseini SM, Kim R, Udupa S, et al. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation, 2018.
- DiStefano MT, Goehringer S, Babb L, et al. The Gene Curation Coalition: a global effort to harmonize gene-disease evidence resources. Genetics in Medicine, 2022.
- Biesecker LG, Harrison SM. The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genetics in Medicine, 2018.